Via: OncoMed
REDWOOD CITY, Calif., March 19, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and immuno-oncology candidates in a total of seven presentations at the upcoming American Association of Cancer Research (AACR) Meeting to be held April 18-22, 2015 in Philadelphia, PA.
Among the presentations will be data looking at synergies between anti-DLL4 and anti-PD1 antibodies, as well as between Wnt-pathway inhibitors and taxanes; biomarker research for tarextumab (anti-Notch2/3), brontictuzumab (anti-Notch1) and anti-RSPO3; and research related to the Hippo anti-cancer stem cell pathway.
Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=902462
RSS Feed
